Skip to main content
Premium Trial:

Request an Annual Quote

Omicia Wins $788K NHGRI Grant to Refine Disease Marker Annotation System

NEW YORK (GenomeWeb News) — Omicia has been awarded a $788,517 Phase II Small Business Innovation Research grant from the National Human Genome Research Institute to help it refine its disease marker genome-annotation system, the firm said today.
 
According to Omicia, the goal of the project is  to “facilitate the development of diagnostic profiles for a diverse array of disease conditions.”
 
Privately held Omicia said that the system uses information from databases that catalog genetic variations to computationally map clinical disease information directly onto the human genome sequence.
 
The company received a $99,757 Phase I SBIR grant last year to help it develop the system.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.